Seat­tle Ge­net­ic­s' Astel­las-part­nered ADC nails con­fir­ma­to­ry PhI­II in urothe­lial can­cer

Nine months af­ter Seat­tle Ge­net­ics nabbed an ac­cel­er­at­ed ap­proval for its Astel­las-part­nered an­ti­body-drug con­ju­gate Pad­cev, the part­ners said the ther­a­py has nailed a con­fir­ma­to­ry Phase III, prov­ing its worth in lo­cal­ly ad­vanced or metasta­t­ic urothe­lial can­cer.

Pad­cev, which has wide­ly been tapped as a po­ten­tial block­buster, scored im­prove­ments in both over­all sur­vival and pro­gres­sion-free sur­vival com­pared to chemother­a­py, caus­ing a 30% re­duc­tion in risk of death (p = 0.001) and 39% re­duc­tion in risk of dis­ease pro­gres­sion or death (p<0.00001).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER